newmeds – the work leading to these results has received funding from the innovative medicines...
TRANSCRIPT
NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI)
NEWMEDSNovel MEthods leading to
NeW MEdications in Depressionand Schizophrenia
IMI JU: Vision and Objective
Vision“Creating Biomedical Research & Development Leadership
for Europe to the Benefit of Patients and Society”
ObjectivesSupport of a faster discovery and development of better
medicines for patients
Enhancement of Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector
2
3
What is NEWMEDS?
NEWMEDS is
an international consortium of scientists that has launched one of the largest ever research academic-industry collaboration projects
to find new methods for the development of drugs for schizophrenia and depression.
4
The Consortium
5
Who are the members in NEWMEDS?
EFPIA companies
H Lundbeck A/S, AstraZeneca AB, Eli Lilly and Company Ltd, Janssen Pharmaceutica NV, Novartis Pharma AG, Orion Corporation, Pfizer Limited, F. Hoffmann-La Roche AG, Institut de Recherches Servier
Universities
King’s College London (UK), Karolinska Institutet (Sweden), The University of Cambridge (UK), Central Institute of Mental Health (Germany), CSIC (Spain), The University of Manchester (UK), Bar Ilan University (Israel)
SME‘s
Psynova Neurotech Ltd (UK), deCODE genetics (Iceland), GABO:mi (Germany)
6
NEWMEDS Workpackage Leads
7
Who are the key contacts in NEWMEDS?
Coordinator: H Lundbeck A/S, Copenhagen, Dr Tine Bryan Stensbøl
Leader of the Managing Entity: King’s College London, London, Prof Shitij Kapur
Project Office: GABO:milliarium mbH & Co. KG, Munich, Kathrin Stoller
www.newmeds-europe.com
8
What is the intention of NEWMEDS?
NEWMEDS brings together top scientists from academic institutions with a wide range of expertise, and partners them with nearly all major biopharmaceutical companies.
The project will focus on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia.
The project will develop standardised paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development.
9
What is the intention of NEWMEDS?
NEWMEDS will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient.
Finally, it will try and develop new approaches for shorter and more efficient trials of new medication – trials that may require fewer patients and give faster results.
10
Who supports NEWMEDS?
NEWMEDS is funded by the Innovative Medicines Initiative (IMI), a unique large scale public-private partnership between the European Union (represented by the European Commission) and the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations, EFPIA).
IMI aims to put Europe at the forefront of biopharmaceutical innovation and to support more efficient discovery and development of better medicines for patients.
www.imi.europa.eu
11
Key data for NEWMEDS
Start date: 1 September 2009
Runtime: 5 years
Structure: 11 Workpackages
Clusters: System based animal models (A)
Translational Technology (B)
Patient Stratification (C)
12
NEWMEDS science in a nutshell
13
InnovativeMedicines
Cro
ss specie
s ima
ging
Mo
dels/M
ea
sure
s of C
ogn
ition
Circu
it-based
Mod
els
CNV genetics t
o novel p
athways
Pharmaco
genetic P
redict
ors
Transla
tional P
roteomic
markers
Novel c
linica
l trial d
esigns
C
A
B Human fMRI-based models
PET based neurocehmistry
Improved image analysis
Systems based
animal models
Tran
slat
iona
l
Tech
nolo
gy
Patient
Stratification
InnovativeMedicines
Cro
ss specie
s ima
ging
Mo
dels/M
ea
sure
s of C
ogn
ition
Circu
it-based
Mod
els
CNV genetics t
o novel p
athways
Pharmaco
genetic P
redict
ors
Transla
tional P
roteomic
markers
Novel c
linica
l trial d
esigns
C
A
B Human fMRI-based models
PET based neurocehmistry
Improved image analysis
Systems based
animal models
Tran
slat
iona
l
Tech
nolo
gy
Patient
Stratification